7.87 USD
-0.05 (-0.63%)
7.87 USD
0 (0%)
Taking everything into account, DERM scores 2 out of 10 in our fundamental rating. DERM was compared to 192 industry peers in the Pharmaceuticals industry. DERM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, DERM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year DERM has reported negative net income.
In the past year DERM has reported a negative cash flow from operations.
In the past 5 years DERM reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of -10.17%, DERM is doing good in the industry, outperforming 66.49% of the companies in the same industry.
Looking at the Return On Equity, with a value of -33.45%, DERM is in line with its industry, outperforming 59.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.17% | ||
| ROE | -33.45% | ||
| ROIC | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of DERM (64.40%) is better than 73.30% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
DERM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
2. Health
2.1 Basic Checks
DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
DERM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DERM has more shares outstanding
DERM has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.64, we must say that DERM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.64, DERM is in line with its industry, outperforming 49.74% of the companies in the same industry.
DERM has a Debt/Equity ratio of 0.75. This is a neutral value indicating DERM is somewhat dependend on debt financing.
DERM's Debt to Equity ratio of 0.75 is on the low side compared to the rest of the industry. DERM is outperformed by 69.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.64 |
ROIC/WACCN/A
WACC9.61%
2.3 Liquidity
DERM has a Current Ratio of 1.42. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.42, DERM is doing worse than 71.73% of the companies in the same industry.
DERM has a Quick Ratio of 1.12. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
DERM's Quick ratio of 1.12 is on the low side compared to the rest of the industry. DERM is outperformed by 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 41.41% over the past year.
DERM shows a small growth in Revenue. In the last year, the Revenue has grown by 2.82%.
DERM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.96% yearly.
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
3.2 Future
DERM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.50% yearly.
DERM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.53% yearly.
EPS Next Y53.25%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year14.82%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 30.56, the valuation of DERM can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DERM indicates a somewhat cheap valuation: DERM is cheaper than 71.73% of the companies listed in the same industry.
DERM is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.83, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.56 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DERM's earnings are expected to grow with 48.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.08%
EPS Next 3Y48.5%
5. Dividend
5.1 Amount
No dividends for DERM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.87
-0.05 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.24%
Inst Owner Change34.03%
Ins Owners15.49%
Ins Owner Change11.47%
Market Cap166.37M
Revenue(TTM)59.40M
Net Income(TTM)-8.66M
Analysts82
Price Target13.77 (74.97%)
Short Float %16.75%
Short Ratio12.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.58%
Min EPS beat(2)-85.76%
Max EPS beat(2)-49.39%
EPS beat(4)2
Avg EPS beat(4)-12.79%
Min EPS beat(4)-85.76%
Max EPS beat(4)58.28%
EPS beat(8)2
Avg EPS beat(8)-31.88%
EPS beat(12)4
Avg EPS beat(12)26.25%
EPS beat(16)5
Avg EPS beat(16)-0.28%
Revenue beat(2)0
Avg Revenue beat(2)-4.89%
Min Revenue beat(2)-8.32%
Max Revenue beat(2)-1.46%
Revenue beat(4)1
Avg Revenue beat(4)-2.25%
Min Revenue beat(4)-8.32%
Max Revenue beat(4)6.86%
Revenue beat(8)2
Avg Revenue beat(8)-1.81%
Revenue beat(12)4
Avg Revenue beat(12)5.69%
Revenue beat(16)5
Avg Revenue beat(16)1.83%
PT rev (1m)12.5%
PT rev (3m)14.41%
EPS NQ rev (1m)-212.5%
EPS NQ rev (3m)-197.83%
EPS NY rev (1m)-48.41%
EPS NY rev (3m)-65.49%
Revenue NQ rev (1m)-13.88%
Revenue NQ rev (3m)-14.77%
Revenue NY rev (1m)-6.2%
Revenue NY rev (3m)-6.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.56 | ||
| P/S | 2.8 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.42 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)0.26
Fwd EY3.27%
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS2.81
BVpS1.23
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.17% | ||
| ROE | -33.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.4% | ||
| FCFM | N/A |
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 0.64 |
F-Score5
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y53.25%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
Revenue Next Year14.82%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
EBIT growth 1Y44.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.12%
EBIT Next 3Y84.38%
EBIT Next 5YN/A
FCF growth 1Y-246.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.93%
OCF growth 3YN/A
OCF growth 5YN/A
JOURNEY MEDICAL CORP / DERM FAQ
What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?
ChartMill assigns a fundamental rating of 2 / 10 to DERM.
What is the valuation status for DERM stock?
ChartMill assigns a valuation rating of 2 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.
What is the profitability of DERM stock?
JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.
Can you provide the financial health for DERM stock?
The financial health rating of JOURNEY MEDICAL CORP (DERM) is 1 / 10.